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Abstract
Background: The incidence of hepatocellular carcinoma (HCC) is increasing, but surgical manage-
ment continues to be underutilized. This retrospective review investigates treatment decisions and
survival for early stage HCC.
Methods: The National Cancer Database (NCDB) was queried for all patients with curable HCC (Stage
I/II) from 1998 to 2011 (n = 43 859). Patient and tumour characteristics were analysed to determine
predictors of having surgery and of long-term survival.
Results: Only 39.7% of patients received surgery for early stage HCC. Surgical therapies included
resection (34.6%), transplant (28.7%), radiofrequency ablation (27.1%) and other therapies. Surgery
correlated with improved median survival (48.3 versus 8.4 months), but was only performed on 42% of
stage I patients and 50% of tumours smaller than 2 cm. Patients were more likely to receive surgery if
they were Asian or white race, had private insurance, higher income, better education, or treatment at
an academic centre (P < 0.05). However, private insurance and treatment at an academic centre were
the only variables associated with improved survival (P < 0.05).
Conclusion: Fewer than half of patients with curable HCC receive surgery, possibly as a result of
multiple socioeconomic variables. Past these barriers to care, survival is related to adequate and reli-
able treatment. Further efforts should address these disparities in treatment decisions.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
solid organ tumour and the third leading cause of cancer-
related death worldwide.1 The incidence of HCC has been
increasing for years, but incidence-based mortality has slowed,
probably owing to earlier detection and intervention.2 How-
ever, there is a large population of patients with curable disease
who do not receive surgical management. A recent meta-analy-
sis found an average rate of curative intent surgery of 22%,
ranging from 14 to 51%.3 Rates were higher in single-centre
studies, and the rate for early stage HCC was 59%. Rates of
surgical management in other studies range from 20 to 57%.4–7
While the phenomenon of underutilized surgical care is known,
the reasons for this disparity remain unclear.
The present study aims to provide a comprehensive under-
standing of surgical management for early stage HCC. This
analysis utilized a nationally validated, prospectively gathered,
cancer database to investigate how many patients with poten-
tially curable disease receive surgical management and what
variables are associated with treatment decisions and survival.
Patients and methods
Data source
Data for this study were drawn from the American College of
Surgeons National Cancer Data Base (NCDB) liver Participant
User File (PUF) for the years 1998–2011. This is a nationwide,
This study was presented at the Annual Meeting of the AHPBA, 11-15
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facility-based, clinical data set that captures 70% of all diagnosed
malignancies in the US.8 The NCDB collects de-identified
patient-level data from nationally accredited cancer programme
registries using standardized data items and coding definitions.
These data include patient demographics as well as detailed
information regarding cancer staging, tumour histology, treat-
ment types and courses, short-term surgical outcomes, and
long-term survival.
Patient cohort
The liver PUF was queried for all patients with clinical stage I/II
HCC (n = 43 859), according to the AJCC Cancer Staging Man-
ual edition in use during the year in which the case was diag-
nosed. Subtypes of HCC were excluded. Patients were separated
into groups who did and did not receive surgical management,
defined as surgical resection, liver transplant, radiofrequency
ablation and other liver-directed therapies. The following patient
information was collected for all patients: age (years), gender,
race (Asian, black, white or other), primary insurance, income
(median household income for patient zip code based on 2000
US Census data, in quartiles), education (median percentage of
adults in the patient’s zip code without a high school degree
[HSD] based on 2000 US Census data, in quartiles), tumour
grade, tumour size (<2 cm, 2–5 cm, >5 cm), AJCC clinical stage
(I or II), patient Charlson/Deyo comorbidity score (0,1,2), facil-
ity type (academic: > 500 new cancer diagnoses annually, at least
four postgraduate training programmes; comprehensive com-
munity: >500 new cancer diagnoses annually, postgraduate
training optional; community: 100–500 new cancer diagnoses
annually, postgraduate training optional; and other), Urban/
Rural status (metropolitan, urban, rural), great circle distance
(distance in miles between patient’s residence and reporting hos-
pital), surgical procedure (resection, transplant, radiofrequency
ablation, other/unknown) for patients who had surgery and
AJCC pathological stage (I–IV) for patients who had surgery.
Statistical analysis
The two cohorts were compared with respect to the variables
above using chi-squared tests for categorical variables and
rank-sum tests for continuous variables. Kaplan–Meier survival
analysis was used to compare survival between the two groups.
For survival analyses, data were limited to the years 1998–2006
to ensure appropriate follow-up. As a result of this and limita-
tions based on missing data, only 15 235 patients (10.2%) were
included in the survival analysis. Multiple logistic regression
models were created to analyse predictors of having surgery
and 30-day mortality; Cox regression was used to model long-
term survival. The following variables of clinical interest were
included in the models: clinical stage, age, gender, race, pri-
mary insurance, income, education, Charlson–Deyo score and
facility type. An alpha level of 0.05 was used for all significance
tests. The data were analysed using SAS 9.3 (SAS Institute,
Cary, NC, USA).
Results
Patient, tumour and facility characteristics
Table S1 (available online as Supporting Information) describes
the cohorts of patients who did and did not receive surgical man-
agement for the stage I/II HCC. Overall, not quite 40% of
patients received surgical management. The rates of surgical
management over time in this cohort are presented in Fig. 1.
Patients who received surgery were younger, less likely to be black
and more often privately insured. Income and education were
directly correlated with increasing rates of surgical management.
Surgical therapy was more common for smaller tumours.
However, tumours graded as ‘moderately differentiated’ were
most likely to receive surgery. Post-operatively, only 5.9% of
tumours were upstaged to stage III or IV, and none were
downstaged to stage 0. Also of note, patients with a Charlson–
Deyo score of 0 were less often managed surgically.
Surgical therapy was much more common in academic cen-
tres than community centres. There was little variation based
on urban/rural designation, but patients who ended up having
surgery travelled further for their care than patients who did
not.
Predictors of surgery and post-operative mortality
Results from the multivariate analysis for predictors of receiv-
ing surgical management are in Table 1. Asian patients were
more likely than whites to receive surgery, and black patients
were less likely. Lower odds of surgery were associated with
clinical stage II versus I, increasing age and male gender. Also
less likely to have surgery were patients without private insur-
ance, with low income, with less education and those not trea-
ted at academic centres.
Figure 1 Percentage of patients per year with stage I/II
hepatocellular carcinoma (HCC) who have surgical management.
RFA, radiofrequency ablation
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Of patients who received surgical management, several fac-
tors were associated with increased odds of post-operative
mortality (Table 2): increasing age, government insurance and
treatment at a comprehensive community cancer programme.
Long-term survival
Figure 2 shows the survival benefit for patients who had surgi-
cal. Multivariate Cox analysis (Table 3) confirmed that surgery
was associated with a survival benefit, as was Asian race. Clini-
cal stage II and increasing age were associated with inferior
survival. Other correlates of inferior survival included non-pri-
vate insurance as well as treatment of a comprehensive com-
munity cancer.
Table 1 Multivariate analysis of predictors of having surgery for
stage I/II hepatocellular carcinoma (HCC) patients in the National
Cancer Data Base (NCDB)
Variable Odds ratio 95% CI P-value
Clinical Stage 2 (versus 1) 0.73 0.70–0.76 <0.001
Age (1 year increase) 0.98 0.98–0.98 <0.001
Male 0.92 0.87–0.97 0.001
Race
White 1.00
Asian 1.34 1.23–1.45 <0.001
Black 0.82 0.77–0.88 <0.001
Other 0.99 0.85–1.15 0.888
Insurance
Private 1.00
Medicare 0.83 0.78–0.88 <0.001
Medicaid 0.53 0.50–0.57 <0.001
Not Insured 0.32 0.28–0.36 <0.001
Other 0.78 0.65–0.92 0.003
Income
>$46 000 1.00
$35 000–46 000 0.96 0.90–1.03 0.238
$30 000–35 000 0.88 0.81–0.95 0.001
<$30 000 0.92 0.84–1.00 0.048
Education
<14% 1.00
14–20% 0.87 0.81–0.93 <0.001
20–29% 0.86 0.80–0.93 <0.001
>29% 0.72 0.66–0.78 <0.001
Charlson–Deyo Score
0 1.00
1 1.31 1.24–1.38 <0.001
2 1.21 1.14–1.27 <0.001
Facility
Academic Programme 1.00
Community Cancer
Programme
0.31 0.28–0.35 <0.001
Comprehensive
Community
Cancer Programme
0.53 0.50–0.55 <0.001
Other Cancer Programme 0.16 0.10–0.25 <0.001
Table 2 Multivariate analysis of predictors of 30-day mortality for
stage I/II hepatocellular carcinoma (HCC) patients in the National
Cancer Data Base (NCDB) who received surgical management
Variable Odds ratio 95% CI P-value
Clinical Stage 2 (versus 1) 1.00 0.79–1.27 0.98
Age (1 year increase) 1.04 1.02–1.05 <0.001
Male 1.09 0.85–1.40 0.491
Race
White 1.00
Asian 0.74 0.47–1.16 0.193
Black 0.84 0.58–1.22 0.363
Other 1.64 0.84–3.17 0.145
Insurance
Private 1.00
Medicare 1.37 1.02–1.83 0.037
Medicaid 2.30 1.59–3.33 <0.001
Not Insured 2.07 0.99–4.35 0.054
Other 1.63 0.69–3.83 0.262
Income
>$46 000 1.00
$35 000–46 000 1.23 0.89–1.70 0.208
$30 000–35 000 1.19 0.81–1.76 0.372
<$30 000 1.47 0.95–2.27 0.088
Education
<14% 1.00
14–20% 1.24 0.89–1.75 0.202
20–29% 1.16 0.80–1.68 0.424
>29% 1.22 0.80–1.87 0.352
Charlson–Deyo Score
0 1.00
1 1.05 0.81–1.38 0.711
2 1.19 0.91–1.57 0.212
Facility
Academic Programme 1.00
Community Cancer
Programme
0.96 0.44–2.08 0.910
Comprehensive Community
Cancer Programme
1.34 1.04–1.72 0.021
Other Cancer Programme 1.51 0.20–11.7 0.691
CI, confidence interval; education, percentage of people in the
patient’s zip code without a high school degree.
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Subgroups of non-surgical patients
In an effort to better understand the types of patients with cur-
able HCC who did not receive surgical management, we per-
formed a subset analysis on three groups of non-surgical
patients: those with small tumours (<2 cm), stage I cancer or
no comorbidities (Charlson–Deyo score = 0). As seen in
Table S2 (available online as Supporting Information) these
patients differ in several ways from the patients in Table S1
(available online as Supporting Information) who had surgery.
Patients in these groups were more often of black race, lower
income, less education and treated at a community centre.
They were also less likely to have private insurance and more
likely to be uninsured.
Discussion
This updated analysis of the treatment of early stage HCC
demonstrates that surgical treatment is still quite underused in
a potentially curable cancer. Surgery was associated with sig-
nificantly increased survival among patients with stage I/II
HCC, and yet < 40% of patients were managed surgically.
Moreover, non-medical patient factors appear to be associated
with this treatment decision. While reported rates of resect-
ability for HCC are lower than 40%, this analysis focuses on
early stage HCC and is the most nationally representative
study to do so.
Several previous studies have identified possible explanations
for this underutilization of surgical therapy. Some have sug-
gested that demographic factors, such as race or socioeconomic
status, influence the use of surgery for HCC.3,5,9–11 While
socioeconomic factors may influence treatment, it is unclear if
they affect survival.4,9,12,13 It has also been suggested that the
location and type of hospital are important factors affecting
treatment patterns.6,7 However, many of these studies are lim-
ited by a reliance on data from a single institution or Medi-
care, and may not accurately represent national treatment
patterns for all patients with HCC.
Figure 2 Kaplan–Meier survival analysis of all stage I/II
hepatocellular carcinoma (HCC) patients in the National Cancer
Data Base (NCDB) based on whether or not they received surgical
management
Table 3 Multivariate analysis of predictors of survival for all stage
I/II hepatocellular carcinoma (HCC) patients in the National Cancer
Data Base (NCDB)
Variable Hazard ratio 95% CI P-value
Having surgery 0.74 0.70–0.78 <0.001
Clinical Stage 2 (versus 1) 1.06 1.02–1.11 0.001
Age 1.01 1.00–1.01 <0.001
Male 1.04 0.99–1.10 0.121
Race
White 1.00
Asian 0.84 0.77–0.91 <0.001
Black 1.05 0.98–1.12 0.216
Other 0.95 0.80–1.13 0.572
Insurance
Private 1.00
Medicare 1.11 1.05–1.18 0.001
Medicaid 1.15 1.06–1.24 0.001
Not Insured 1.14 1.01–1.28 0.037
Other 1.10 0.90–1.36 0.355
Income
>$46 000 1.00
$35 000–46000 1.04 0.97–1.11 0.262
$30 000–35000 1.05 0.97–1.13 0.257
<$30000 1.06 0.97–1.16 0.234
Education
<14% 1.00
14–20% 1.03 0.96–1.11 0.383
20–29% 1.03 0.96–1.11 0.416
>29% 1.01 0.93–1.10 0.821
Charlson–Deyo Score
0 1.00
1 1.02 0.96–1.07 0.542
2 1.02 0.96–1.08 0.494
Facility
Academic Programme 1.00
Community Cancer
Programme
1.07 0.98–1.17 0.154
Comprehensive Community
Cancer Programme
1.07 1.02–1.13 0.009
Other Cancer Programme 0.92 0.74–1.15 0.463
CI, confidence interval; education, percentage of people in the
patient’s zip code without a high school degree.
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In this study, several patient characteristics were associated
with a less likelihood of surgical management, higher 30-day
mortality and inferior long-term survival. Not surprisingly, older
patients and those with stage II (compared to stage I) fared worse
in all three of these categories. Patients on Medicare, Medicaid
or without insurance were less likely to have surgery, and those
that did have worse outcomes. Insurance status has previously
been shown to affect treatment and survival.5,9,14 While these
studies also showed that treatment was affected by increased
stage at presentation, with privately insured patients presenting
earlier, this study has shown that mortality and survival are dif-
ferent even among early stage HCC. Also, as government insur-
ance is being expanded nationally,15 it is important to have a
thorough understanding of how Medicaid and Medicare out-
comes compare to those of privately insured patients.
In contrast to insurance status, patient socioeconomic status
played a different role. Patients who were black had lower
income or less education were significantly less likely to receive
surgical treatment. However, when considering HCC patients
who received surgery, these factors did not impact 30-day
mortality or survival. These contrasting findings highlight the
importance of access to care. Socioeconomic status matters for
a variety of reasons, but perhaps a patient’s race, education or
income affects his/her cancer survival much less than the avail-
ability of appropriate and reliable treatment. This was further
supported by the sub-analysis of non-surgical patients
(Table S2, available online as Supporting Information); while
race, income and education of these patients were different
from surgically managed patients, the most striking difference
between the groups was the rate of uninsured patients.
Another variation in care and outcomes was based on treat-
ment facilities. In this analysis, academic cancer centres per-
formed vastly more surgery on early stage HCC than did
community cancer centres. Also, comprehensive community
cancer centres, as designated by the NCDB, had worse 30-day
mortality and inferior survival compared with academic cen-
tres. Prior studies have shown that hospital type can influence
treatment decisions16,17 and outcomes.18–20 Although interna-
tionally accepted consensus treatment, guidelines are available,
such as the BCLC staging system,21 they do not account for
disparities in patient and hospital resources. For example,
hospitals without adequate radiofrequency ablation (RFA) or
transplant services, or patients without reliable financial and
social support, are unable to adhere to such guidelines. These
data suggest that academic hospitals may be better suited to
handle the type of complicated, multi-disciplinary care that
HCC requires than their community counterparts.
This study has limitations owing to its retrospective and
administrative nature. The results only identify correlations
and were not able to define causation. Also, some data fields
are vague or possibly incorrectly populated. For example, the
documented reason for most patients who did not receive
surgery was ‘not part of first planned treatment’ without any
further explanation. Because of this, we are unable to under-
stand truly how comorbidities, patient and provider preference,
hospital resources and other specific variables affect treatment
decisions. For example, we could not evaluate the role of or
patient preference or degree of liver disease. Survival analyses
are also limited owing to missing values in some data fields.
The NCDB does not provide specific treatment centre charac-
teristics other than geographic area and academic/community
designation, so further investigations into nuanced differences
between hospitals and what affects treatment decisions are lim-
ited. Also, the ‘other’ surgical category represents a variety of
interventional techniques, including transarterial therapy and
cryosurgery, which are quite different from surgical resection
and transplantation. Finally, while the use of patient zip codes
and census data is a validated method to compare socioeco-
nomic measures,20,22,23 it is a surrogate for more granular
patient data and potentially confounds the results.
In conclusion, this analysis has shown that surgery
improves survival for patients with early stage HCC, but it is
vastly underutilized in the United States. Socioeconomic fac-
tors, as well as type of facility, seem to affect these treatment
decisions. These data suggest that a key barrier is getting
patients to the appropriate centre for cancer treatment, as
race and socioeconomic status were not associated with differ-
ences in survival. In order to improve survival for the grow-
ing number of patients with HCC, further research is
necessary to understand the specific barriers to care for
patients with curable disease.
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